Anti-Hepatitis A-Virus (HAV) IgM ELISA Kit

Sample

Serum and plasma

Species Reactivity

Human

Detection Method

iELISA

Intended Use

The Anti-HAV IgM ELISA Kit is an enzyme immunoassay for research use for the qualitative and quantitative detection of IgM antibodies in human serum or plasma directed against the Hepatitis A-Virus.

Contents of Kit

1. Microtiter plate: ready for use, coated with an antibody directed against human IgM antibodies (anti-μ-chain). Wells are separately breakable. (8x12) wells
2. Conjugate Concentrate (KK): 100-fold concentrated (peroxidase labeled Anti-HAV IgG). 1 x 250 μL
3. Hepatitis A Virus antigen (AG): inactivated, ready for use. 1 x 13.5 mL
4. Positive Control (PK): ready for use, recalcificated human plasma, reactive for anti-HAV-IgM, Titre > 1:10000. 1 x 2 mL
5. Negative Control (NK): ready for use, recalcificated human plasma, not reactive for anti-HAV-IgM/IgG. Anti-HBsAg, anti-HIV and anti-HCV negative. 1 x 1 mL
6. Dilution Buffer (VP): ready for use. Please shake before use! 1 x 120 mL
7. Washing Buffer (WP): 20-fold concentrated solution. 1 x 50 mL
8. Substrate (S): ready for use, horseradish-peroxidase-(HRP) substrate, stabilised Tetramethylbencidine (TMB). 1 x 12 mL
9. Stopping Solution (SL): ready for use, 0.2 M sulfuric acid. 1 x 12 mL
10. Sealing Tape: for covering the microtiter plate. 2

Storage

Store the kit at 2-8°C after receipt until its expiry date. Avoid repeated thawing and freezing.
The shelf life of the components after initial opening is warranted for 4 weeks, store the unused strips and microtiter wells airtight together with the desiccant at 2-8°C in the clip-lock bag, use in the frame provided. The 1:20 diluted Washing Buffer WP is 4 weeks stable at 2-8°C

General Description

The detection of anti-HAV IgM (IgM antibodies specific for Hepatitis A virus) in the serum or plasma of patients indicates a fresh infection with the Hepatitis-A virus. Depending on the anti HAV IgM titre it is possible to differentiate between an acute infection (1 - 3 months after the start of clinical symptoms) and early convalescence (3 - 6 months). In rare cases (approx. 10% of all clinical cases) the anti-HAV IgM response remains positive (6 - 12 months).